ACCG-2671 is an oral small molecule amylin receptor agonist which acts through complementary satiety pathways in the ...

The scientific wonderers at What If redesign human skeletal structure and muscle groups to see how a return to quadrupedal ...

A new systematic review and meta-analysis appearing in the Journal of Sport and Health Science suggests that combining strength and aerobic exercise may offer greater improvements ...

The biology behind muscle pain: calcium chaos, microscopic damage, and the overlooked mechanism that explains how statins can ...

The MarketWatch News Department was not involved in the creation of this content.-- As demand for non-surgical aesthetic solutions surges, Lumenis launches a platform that targets ...

The health technology provider scheduled demonstrations of medical-grade artificial intelligence systems at the retirement ...

Lumenis Be Ltd., a leading energy-based medical device company for aesthetic and eye care applications, announced the commercial launch of triLIFT 2.0™: a next generation platform for facial and body ...

New research shows how muscular dystrophy (DM1) damages the heart over time, stressing the need for early diagnosis and ...

Scientists have identified a little-known receptor, GPR133, as a powerful regulator of bone strength. By activating it with a newly discovered compound called AP503, they were able to boost bone ...

This 2026 informational report from Hume Health outlines the company's published Hume Body Pod accuracy positioning, ...

There is growing demand for treatments that can safely prevent and reverse bone loss over time. Osteoporosis, a condition that weakens bones and makes ...

Detailed price information for Sarepta Therapeutics (SRPT-Q) from The Globe and Mail including charting and trades.